The Food and Drug Administration has cleared three Hitachi gammacameras that are the centerpiece of the vendor's planned comebackin nuclear medicine. Two of the cameras are systems manufacturedby Hitachi and formerly marketed by Summit Nuclear, while
The Food and Drug Administration has cleared three Hitachi gammacameras that are the centerpiece of the vendor's planned comebackin nuclear medicine. Two of the cameras are systems manufacturedby Hitachi and formerly marketed by Summit Nuclear, while anotheris a new variable-angle digital dual-head product Hitachi hasdeveloped (SCAN 10/11/94).
Hitachi made hardware and software changes to the former Summitcameras and sought FDA clearance for the updates, according toMike Uehara, president of Hitachi Medical Corp. of America inTarrytown, NY. The single-head camera will be marketed as SpectraDigital150DS while the dual-head will receive the product name SpectraDigital260DS.
The new variable-angle dual-head system has been named SpectraDigitalV250DSP. The camera employs an analog-to-digital converter oneach photomultiplier tube and uses digital signal processors fordecoding, according to Uehara. The older cameras do not use digitalsignal processors.
Hitachi is tentatively planning to display the cameras at theSociety of Nuclear Medicine meeting in June and has reserved boothspace at the conference. The company will make a final decisionin March on whether to attend, Uehara said.
In other Hitachi product clearance news, the FDA gave the nodto the company's unique rotational angiography system, SF-VA100.Rather than using a more traditional C-arm configuration, thesystem's x-ray tube is located in a gantry that spins around thepatient. SF-VA100 could be an alternative to biplane angiographyrooms. Fourteen systems have been installed in Japan.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
What Emerging CT Research Reveals About Obesity and Post-Op Survival for Non-Small Cell Lung Cancer
January 29th 2025For those without low skeletal muscle mass on CT and myosteatosis, obese patients have a 23 percent lower risk of death than non-obese patients after undergoing curative resection for non-small cell lung cancer, according to newly published research.